|
1
|
Ettinger DS, Akerley W, Bepler G, Blum MG,
Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, et
al; NCCN Non-Small Cell Lung Cancer Panel Members, . Non-small cell
lung cancer. J Natl Compr Canc Netw. 8:740–801. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group, : Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stroun M, Lyautey J, Lederrey C,
Olson-Sand A and Anker P: About the possible origin and mechanism
of circulating DNA apoptosis and active DNA release. Clin Chim
Acta. 313:139–142. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Volik S, Alcaide M, Morin RD and Collins
C: Cell-free DNA (cfDNA): Clinical significance and utility in
cancer shaped by emerging technologies. Mol Cancer Res. 14:898–908.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jung K, Fleischhacker M and Rabien A:
Cell-free DNA in the blood as a solid tumor biomarker—a critical
appraisal of the literature. Clin Chim Acta. 411:1611–1624. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chiappetta C, Anile M, Leopizzi M, Venuta
F and Della Rocca C: Use of a new generation of capillary
electrophoresis to quantify circulating free DNA in non-small cell
lung cancer. Clin Chim Acta. 425:93–96. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ulivi P, Mercatali L, Casoni GL, Scarpi E,
Bucchi L, Silvestrini R, Sanna S, Monteverde M, Amadori D, Poletti
V, et al: Multiple marker detection in peripheral blood for NSCLC
diagnosis. PLoS One. 8:e574012013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cargnin S, Canonico PL, Genazzani AA and
Terrazzino S: Quantitative analysis of circulating cell-free DNA
for correlation with lung cancer survival: A systematic review and
meta-analysis. J Thorac Oncol. 12:43–53. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang T, Zhai C, Su C, Ren S and Zhou C:
The diagnostic value of circulating cell free DNA quantification in
non-small cell lung cancer: A systematic review with meta-analysis.
Lung Cancer. 100:63–70. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sozzi G, Conte D, Leon M, Ciricione R, Roz
L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, et al:
Quantification of free circulating DNA as a diagnostic marker in
lung cancer. J Clin Oncol. 21:3902–3908. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Devonshire AS, Whale AS, Gutteridge A,
Jones G, Cowen S, Foy CA and Huggett JF: Towards standardisation of
cell-free DNA measurement in plasma: Controls for extraction
efficiency, fragment size bias and quantification. Anal Bioanal
Chem. 406:6499–6512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jen J, Wu L and Sidransky D: An overview
on the isolation and analysis of circulating tumor DNA in plasma
and serum. Ann NY Acad Sci. 906:8–12. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lui YY, Chik KW and Lo YM: Does
centrifugation cause the ex vivo release of DNA from blood cells?
Clin Chem. 48:2074–2076. 2002.PubMed/NCBI
|
|
15
|
Jung M, Klotzek S, Lewandowski M,
Fleischhacker M and Jung K: Changes in concentration of DNA in
serum and plasma during storage of blood samples. Clin Chem.
49:1028–1029. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Holdhoff M, Schmidt K, Diehl F, Aggrawal
N, Angenendt P, Romans K, Edelstein DL, Torbenson M, Kinzler KW,
Vogelstein B, et al: Detection of tumor DNA at the margins of
colorectal cancer liver metastasis. Clin Cancer Res. 17:3551–3557.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Q, Zheng H, Hu F, Zhang H, Hu Y, Li
J, Zhang T, Liu Z, Lu B, Hu A, et al: Serum CYFRA21-1 is correlated
with the efficacy of epidermal growth factor receptor-tyrosine
kinase inhibitor in non-small cell lung cancer patients harboring
EGFR mutations. Zhongguo Fei Ai Za Zhi. 19:550–558. 2016.(In
Chinese). PubMed/NCBI
|
|
19
|
Molina-Vila MA, de-Las-Casas CM,
Bertran-Alamillo J, Jordana-Ariza N, González-Cao M and Rosell R:
cfDNA analysis from blood in melanoma. Ann Transl Med.
3:3092015.PubMed/NCBI
|
|
20
|
Chen K, Zhang H, Zhang LN, Ju SQ, Qi J,
Huang DF, Li F, Wei Q and Zhang J: Value of circulating cell-free
DNA in diagnosis of hepatocelluar carcinoma. World J Gastroenterol.
19:3143–3149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cicchillitti L, Corrado G, De Angeli M,
Mancini E, Baiocco E, Patrizi L, Zampa A, Merola R, Martayan A,
Conti L, et al: Circulating cell-free DNA content as blood based
biomarker in endometrial cancer. Oncotarget. 8:115230–115243. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gormally E, Caboux E, Vineis P and Hainaut
P: Circulating free DNA in plasma or serum as biomarker of
carcinogenesis: Practical aspects and biological significance.
Mutat Res. 635:105–117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fawzy A, Sweify KM, El-Fayoumy HM and
Nofal N: Quantitative analysis of plasma cell-free DNA and its DNA
integrity in patients with metastatic prostate cancer using ALU
sequence. J Egypt Natl Cancer Inst. 28:235–242. 2016. View Article : Google Scholar
|
|
24
|
Lo YM, Tein MS, Lau TK, Haines CJ, Leung
TN, Poon PM, Wainscoat JS, Johnson PJ, Chang AM and Hjelm NM:
Quantitative analysis of fetal DNA in maternal plasma and serum:
Implications for noninvasive prenatal diagnosis. Am J Hum Genet.
62:768–775. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee TH, Montalvo L, Chrebtow V and Busch
MP: Quantitation of genomic DNA in plasma and serum samples: Higher
concentrations of genomic DNA found in serum than in plasma.
Transfusion. 41:276–282. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma S, Shen L, Qian N and Chen K: The
prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC
are limited. Cancer Biomark. 10:155–162. 2011-2012. View Article : Google Scholar
|
|
27
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al Spanish Lung Cancer Group in
collaboration with Groupe Français de Pneumo-Cancérologie and
Associazione Italiana Oncologia Toracica, : Erlotinib versus
standard chemotherapy as first-line treatment for European patients
with advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012-2012. View Article : Google Scholar
|
|
28
|
Schwarzenbach H, Müller V, Stahmann N and
Pantel K: Detection and characterization of circulating
microsatellite-DNA in blood of patients with breast cancer. Ann NY
Acad Sci. 1022:25–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ren N, Qin LX, Tu H, Liu YK, Zhang BH and
Tang ZY: The prognostic value of circulating plasma DNA level and
its allelic imbalance on chromosome 8p in patients with
hepatocellular carcinoma. J Cancer Res Clin Oncol. 132:399–407.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoon KA, Park S, Lee SH, Kim JH and Lee
JS: Comparison of circulating plasma DNA levels between lung cancer
patients and healthy controls. J Mol Diagn. 11:182–185. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ludovini V, Pistola L, Gregorc V, Floriani
I, Rulli E, Piattoni S, Di Carlo L, Semeraro A, Darwish S,
Tofanetti FR, et al: Plasma DNA, microsatellite alterations, and
p53 tumor mutations are associated with disease-free survival in
radically resected non-small cell lung cancer patients: a study of
the perugia multidisciplinary team for thoracic oncology. J Thorac
Oncol. 3:365–373. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kamat AA, Baldwin M, Urbauer D, Dang D,
Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL,
et al: Plasma cell-free DNA in ovarian cancer: An independent
prognostic biomarker. Cancer. 116:1918–1925. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jung K, Stephan C, Lewandowski M, Klotzek
S, Jung M, Kristiansen G, Lein M, Loening SA and Schnorr D:
Increased cell-free DNA in plasma of patients with metastatic
spread in prostate cancer. Cancer Lett. 205:173–180. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gautschi O, Bigosch C, Huegli B, Jermann
M, Marx A, Chassé E, Ratschiller D, Weder W, Joerger M, Betticher
DC, et al: Circulating deoxyribonucleic Acid as prognostic marker
in non-small-cell lung cancer patients undergoing chemotherapy. J
Clin Oncol. 22:4157–4164. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kumar S, Guleria R, Singh V, Bharti AC,
Mohan A and Das BC: Efficacy of circulating plasma DNA as a
diagnostic tool for advanced non-small cell lung cancer and its
predictive utility for survival and response to chemotherapy. Lung
Cancer. 70:211–217. 2010. View Article : Google Scholar : PubMed/NCBI
|
